Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987349 · ClinicalTrials.gov registry record · Phase 4
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
A Phase 4 study of Influenza, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT01987349 is a Phase 4 study of Influenza that has completed, run by Stanford University. The registered enrollment target is 72 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01987349, a Phase 4 study of Influenza, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
Conditions Studied
Interventions
- BIOLOGICAL Fluzone® (intramuscular)
- BIOLOGICAL FluMist® (intranasal)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01987349
The ClinicalTrials.gov registry entry for NCT01987349 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Fluzone® (intramuscular) is the first listed.
NCT01987349 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01987349 about?
NCT01987349 is a clinical study titled "T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009". This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
What is the current status of trial NCT01987349?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2009-09. Estimated completion is 2010-01.
What conditions does trial NCT01987349 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01987349?
The interventions under investigation include: Fluzone® (intramuscular) (BIOLOGICAL), FluMist® (intranasal) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01987349?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01987349 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.